Lyra Therapeutics, Inc. (LYRA)
| Market Cap | 140.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.13M |
| Shares Out | 12.96M |
| EPS (ttm) | -2.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $10.47 |
| Previous Close | $10.83 |
| Change ($) | -0.36 |
| Change (%) | -3.32% |
| Day's Open | 10.90 |
| Day's Range | 10.32 - 11.00 |
| Day's Volume | 53,791 |
| 52-Week Range | 8.76 - 22.00 |
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Present LANTERN Phase 2 Study Results for LYR 210 in Oral Presentation at COSM 2021 Virtual
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Lyra Therapeutics (LYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Announces Appointment of Robert Kern, MD, as Chief Medical Officer
LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lyra Therapeutics, Inc. ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Provides Corporate Update and Anticipated Milestones for 2021
LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of CRS
Lyra is to report top line data of its Phase 2 Trial in December. All indications are the trial should be a success, and they have strong backing from Perceptive Advisors.
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors
Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance
Three poster presentations to be featured at the 66th Annual Meeting of the American Rhinologic Society Three poster presentations to be featured at the 66th Annual Meeting of the American Rhinologic So...
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2020 Results - Earnings Call Transcript
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated d...
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated d...
WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated d...
Lyra Therapeutics: Advancing An Innovative Solution For Chronic Rhinosinusitis
WATERTOWN, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated d...
Lyra Therapeutics completed its IPO in late-April selling 3.5m shares at a price of $16 - the higher end of expectations - to raise $56m.
WATERTOWN, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated dr...
Shares of Lyra Therapeutics Inc., a biotech specializing in treatments for ear, nose and throat diseases, soared 32% in their trading debut Friday, after the company's initial public offering priced at ...
When a raging bull market dies and turns into a bear market with a deep recession in less than 45 days, things are not normal.
About LYRA
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase I... [Read more...]
| Industry Biotechnology | IPO Date May 1, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol LYRA |
Analyst Forecasts
According to 4 analysts, the average rating for LYRA stock is "Strong Buy." The 12-month stock price forecast is 26.00, which is an increase of 148.33% from the latest price.